Literature DB >> 14704147

Inhibition of cell proliferation and cell cycle progression by specific inhibition of basal JNK activity: evidence that mitotic Bcl-2 phosphorylation is JNK-independent.

Lihua Du1, Christopher S Lyle, Toria B Obey, William A Gaarde, Jeffrey A Muir, Brydon L Bennett, Timothy C Chambers.   

Abstract

The c-Jun NH(2)-terminal kinase (JNK) subgroup of mitogen-activated protein kinases has been implicated largely in stress responses, but an increasing body of evidence has suggested that JNK also plays a role in cell proliferation and survival. We examined the effect of JNK inhibition, using either SP600125 or specific antisense oligonucleotides, on cell proliferation and cell cycle progression. SP600125 was selective for JNK in vitro and in vivo versus other kinases tested including ERK, p38, cyclin-dependent protein kinase 1 (CDK1), and CDK2. SP600125 inhibited JNK activity and KB-3 cell proliferation with the same dose dependence, suggesting that inhibition of proliferation was a direct consequence of JNK inhibition. Inhibition of proliferation by SP600125 was associated with an increase in the G(2)-M and apoptotic fractions of cells but was not associated with p53 or p21 induction. Antisense oligonucleotides to JNK2 but not JNK1 caused highly significant inhibition of cell proliferation. Wild-type mouse fibroblasts responded similarly with proliferation inhibition and apoptosis induction, whereas c-jun(-/-) fibroblasts were refractory to the effects of SP600125, suggesting that JNK signaling to c-Jun is required for cell proliferation. Studies in synchronized KB-3 cells indicated that SP600125 delayed transit time through S and G(2)-M phases. Correspondingly, JNK activity increased in late S phase and peaked in late G(2) phase. During synchronous mitotic progression, cyclin B levels increased concomitant with phosphorylation of c-Jun, H1 histone, and Bcl-2. In the presence of SP600125, mitotic progression was prolonged, and c-Jun phosphorylation was inhibited, but neither H1 nor Bcl-2 phosphorylation was inhibited. However, the CDK inhibitor roscovitine inhibited mitotic Bcl-2 phosphorylation. These results indicate that JNK, and more specifically the JNK2 isoform, plays a key role in cell proliferation and cell cycle progression. In addition, conclusive evidence is presented that a kinase other than JNK, most likely CDK1 or a CDK1-regulated kinase, is responsible for mitotic Bcl-2 phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14704147     DOI: 10.1074/jbc.M304935200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

1.  Virtual target screening: validation using kinase inhibitors.

Authors:  Daniel N Santiago; Yuri Pevzner; Ashley A Durand; MinhPhuong Tran; Rachel R Scheerer; Kenyon Daniel; Shen-Shu Sung; H Lee Woodcock; Wayne C Guida; Wesley H Brooks
Journal:  J Chem Inf Model       Date:  2012-07-23       Impact factor: 4.956

2.  Basal p38 mitogen-activated protein kinase regulates unliganded glucocorticoid receptor function in airway smooth muscle cells.

Authors:  Belaid Bouazza; Manel Debba-Pavard; Yassine Amrani; Lauren Isaacs; Danielle O'Connell; Sara Ahamed; Danielle Formella; Omar Tliba
Journal:  Am J Respir Cell Mol Biol       Date:  2014-02       Impact factor: 6.914

3.  Identification of the major phosphorylation site in Bcl-xL induced by microtubule inhibitors and analysis of its functional significance.

Authors:  Meenakshi Upreti; Elena N Galitovskaya; Rong Chu; Alan J Tackett; David T Terrano; Susana Granell; Timothy C Chambers
Journal:  J Biol Chem       Date:  2008-10-30       Impact factor: 5.157

4.  Purinergic inhibition of Na⁺,K⁺,Cl⁻ cotransport in C11-MDCK cells: Role of stress-activated protein kinases.

Authors:  Olga A Akimova; Sebastien Taurin; Nickolai O Dulin; Sergei N Orlov
Journal:  Purinergic Signal       Date:  2007-06-30       Impact factor: 3.765

5.  c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer.

Authors:  Pablo Vivas-Mejia; Juliana Maria Benito; Ariel Fernandez; Hee-Dong Han; Lingegowda Mangala; Cristian Rodriguez-Aguayo; Arturo Chavez-Reyes; Yvonne G Lin; Mark S Carey; Alpa M Nick; Rebecca L Stone; Hye Sun Kim; Francois-Xavier Claret; William Bornmann; Bryan T J Hennessy; Angela Sanguino; Zhengong Peng; Anil K Sood; Gabriel Lopez-Berestein
Journal:  Clin Cancer Res       Date:  2009-12-22       Impact factor: 12.531

6.  The apoptotic mechanism of action of the sphingosine kinase 1 selective inhibitor SKI-178 in human acute myeloid leukemia cell lines.

Authors:  Taryn E Dick; Jeremy A Hengst; Todd E Fox; Ashley L Colledge; Vijay P Kale; Shen-Shu Sung; Arun Sharma; Shantu Amin; Thomas P Loughran; Mark Kester; Hong-Gang Wang; Jong K Yun
Journal:  J Pharmacol Exp Ther       Date:  2015-01-06       Impact factor: 4.030

7.  Activation of the Jun N-terminal kinase pathway by friend spleen focus-forming virus and its role in the growth and survival of friend virus-induced erythroleukemia cells.

Authors:  Kazuo Nishigaki; Charlotte Hanson; Delores Thompson; Takashi Yugawa; Sandra Ruscetti
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

8.  Up-regulation of SEPT9_v1 stabilizes c-Jun-N-terminal kinase and contributes to its pro-proliferative activity in mammary epithelial cells.

Authors:  Maria E Gonzalez; Olga Makarova; Esther A Peterson; Lisa M Privette; Elizabeth M Petty
Journal:  Cell Signal       Date:  2008-11-18       Impact factor: 4.315

9.  Involvement of c-Jun N-terminal kinase activities in skeletal muscle differentiation.

Authors:  Ashwani Khurana; Chinmoy S Dey
Journal:  J Muscle Res Cell Motil       Date:  2005-02-24       Impact factor: 2.698

Review 10.  Microtubule destabilising agents: far more than just antimitotic anticancer drugs.

Authors:  Darcy Bates; Alan Eastman
Journal:  Br J Clin Pharmacol       Date:  2016-10-18       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.